

**Child with relapsing steroid sensitive
nephrotic syndrome
(≥ 2 relapses in preceding 12 months)**

Randomised (post-recruitment)

Active treatment arm

**Prednisolone administered daily for
6 days commenced within 24 hours
of onset of first URTI**

**Prednisolone administered daily
for 6 days commenced within 24
hours of onset of each
subsequent URTI over 12 month
follow-up period**

Control arm

**No change to current prednisolone
at time of first URTI with
use of placebo tablets to blind study**

**No change to current prednisolone
at time of each subsequent URTI
over 12 month follow-up period
with use of placebo tablets
to blind study**